An Open-Label Study to Evaluate the Safety and Efficacy of Tissue Plasminogen Activator in Treatment of Severe Frostbite

Department of Surgery, Hennepin County Medical Center, Minneapolis, Minnesota 55415, USA.
The Journal of trauma (Impact Factor: 2.96). 01/2006; 59(6):1350-4; discussion 1354-5. DOI: 10.1097/01.ta.0000195517.50778.2e
Source: PubMed


Severe frostbite can have devastating consequences with loss of limbs and digits. One of the mechanisms of cold injury to human tissue is vascular thrombosis. The effect of tissue plasminogen activator (tPA) and heparin in limb and digit preservation in severe frostbite patients has not been previously studied.
Intra-arterial (6 patients) or intravenous (i.v., 13 patients) tPA and IV heparin were used in patients with severe frostbite. All patients between January 1, 1989 and February 1, 2003 with severe frostbite not improved by rapid rewarming, with absent Doppler pulses in distal limb or digits, without perfusion by Technetium (Tc) 99m three-phase bone scan, and no contraindication to tPA use were eligible. Efficacy was assessed on the basis of predicted digit amputation before therapy, given the clinical and Tc-99m scan results, versus partial or complete digits removed.
There were no complications with i.v. tPA. Two patients with intra-arterial TPA had bleeding complications. We know from historical Tc-99m scan data which digits were at risk for amputation. In this study, there were 174 digits at risk in 18 patients and only 33 were amputated.
Intravenous tPA and heparin after rapid rewarming is safe and reduced predicted digit amputations considerably. Patients with no response to thrombolytic therapy were those with more than 24 hours of cold exposure, warm ischemia times greater than 6 hours, or evidence of multiple freeze-thaw cycles. Our algorithm for treatment of severe frostbite now includes use of i.v. tPA for patients without contraindications.

12 Reads
  • Source
    • "Twomey et al. published results of an open-label study to evaluate the safety and efficacy of tissue plasminogen activator (rTPA) in the treatment of severe frostbite found that rTPA and heparin after rapid rewarming is safe and reduced predicted digit amputations. Similar efficacy was reported in both the intravenous and intra-arterial delivery arms [25]. Those patients with more than 24 h of cold exposure, warm ischaemia times greater than 6 h or evidence of multiple freeze-thaw cycles were least likely to benefit [25]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Frostbite presentation to hospital is relatively infrequent, and the optimal management of the more severely injured patient requires a multidisciplinary integration of specialist care. Clinicians with an interest in wilderness medicine/freezing cold injury have the awareness of specific potential interventions but may lack the skill or experience to implement the knowledge. The on-call specialist clinician (vascular, general surgery, orthopaedic, plastic surgeon or interventional radiologist), who is likely to receive these patients, may have the skill and knowledge to administer potentially limb-saving intervention but may be unaware of the available treatment options for frostbite. Over the last 10 years, frostbite management has improved with clear guidelines and management protocols available for both the medically trained and winter sports enthusiasts. Many specialist surgeons are unaware that patients with severe frostbite injuries presenting within 24 h of the injury may be good candidates for treatment with either TPA or iloprost. In this review, we aim to give a brief overview of field frostbite care and a practical guide to the hospital management of frostbite with a stepwise approach to thrombolysis and prostacyclin administration for clinicians.
    04/2014; 3:7. DOI:10.1186/2046-7648-3-7
  • Article: Frostbite.
    Journal of WOCN 35(3):341-6; discussion 347-9. DOI:10.1097/01.WON.0000319135.19176.d8 · 1.18 Impact Factor
Show more